{"id":"NCT00113568","sponsor":"Ferring Pharmaceuticals","briefTitle":"Safety Study of XP12B in Women With Menorrhagia","officialTitle":"Multicenter Study to Evaluate the Safety of XP12B in Women With Heavy Menstrual Bleeding Associated With Menorrhagia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-06","primaryCompletion":"2009-05","completion":"2009-05","firstPosted":"2005-06-09","resultsPosted":"2010-01-20","lastUpdate":"2010-06-15"},"enrollment":784,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Menorrhagia","Heavy Menstrual Bleeding"],"interventions":[{"type":"DRUG","name":"Tranexamic acid tablets (XP12B)","otherNames":["Lysteda","XP12B","tranexamic acid tablets","XP12B-MR"]}],"arms":[{"label":"XP12B (tranexamic acid tablets)","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the safety of XP12B in women with heavy menstrual bleeding associated with menorrhagia.","primaryOutcome":{"measure":"Number of Subjects With at Least One Adverse Event During the Study","timeFrame":"Up to 27 menstrual cycles","effectByArm":[{"arm":"Tranexamic Acid Tablets (XP12B)","deltaMin":678,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":59,"countries":["United States"]},"refs":{"pmids":["21867401","21043553"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":28,"n":723},"commonTop":["Headache","Menstrual discomfort","Back pain","Viral upper respiratory tract infection","Arthralgia"]}}